1
|
POS0260 LONG-TERM HUMORAL RESPONSE TO SARS-CoV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASE. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.5079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundThe first vaccine against SARS-CoV-2 was approved in December 2020. Immunogenicity of SARS-CoV2 vaccines in patients with immune-mediated inflammatory disease (IMID) have so far been evaluated in the 2-6 weeks following complete vaccination and risk groups for poor early vaccine response have been identified leading to specific vaccination recommendations. However, data on the long-term course and persistence of vaccine response in IMID patients, as well as the outcomes of the specific recommendations are lacking.ObjectivesTo evaluate the long-term course of humoral response to SARS-CoV-2 vaccination in a large prospective cohort of IMID patients and non-IMID controls with a follow-up duration of up-to to 10 months after the first vaccine dose.MethodsWe have initiated a prospective dynamic cohort of IMID patients and healthy controls in February 2020 to monitor immune response to SARS-CoV-2 and respiratory infections including COVID-19 (1). Participants who contributed data starting from the 4 weeks before their first vaccination onwards were included in this analysis. Antibodies against SARS-CoV-2 spike protein were quantified with an ELISA from Euroimmun (Lübeck, Germany) with an optical density cutoff of 0.8. We fitted linear mixed-effect models for log-transformed antibody levels using time splines with adjustment for age and sex. Marginal mean antibody levels with 95% confidence intervals (CI) were estimated at selected time points for IMID patients and controls with double vaccination. We descriptively analyzed the observed antibody levels over time in cohort participants receiving two vaccinations vs. three vaccinations.ResultsAmong 5076 cohort participants, 3147 IMID patients and healthy controls (mean (SD) age 49 (16)) provided 4756 samples for this analysis between December 2020 and 2021, with a median (IQR) 28 (14-31) weeks of follow-up after the first vaccination (Table 1). 2965 (94%) participants had received at least 2 and 223 (7%) participants had received three vaccine doses by the date of their latest sampling. In IMID patients, age and sex-adjusted estimated marginal mean antibody levels waned after week 16 and were substantially reduced at all time points compared to the controls, finally dropping to the borderline range (1.01, 95%CI 0.86 to 1.19) at week 40 (Figure 1A, Table 1). A third dose was given to 128 (7%) of IMID patients with a poor response to 2 vaccine doses after a median 20 weeks of the second dose (IQR 10 to 26 weeks). After the third dose, antibody levels in IMID patients were comparable to those of healthy controls at 40 weeks who had three vaccine doses. These were also higher than that of IMID patients and controls who did not receive a third dose (Figure 1B).Table 1.Participant characteristics and antibody levelsHealthy controlsIMID N11991948 Age, mean (SD)40.8 (13.5)54.3 (14.8) Follow-up, weeks, median (IQR)31.1 (23.8-36.6)19.6 (12.3-26.6) Follow-up range, weeks,1.6-46.11.7-46.3Sex, n(%) Female554 (46.2)1136 (58.3)Vaccine intervals, ´median (IQR) 1st to 2nd dose4.6 (3.0-6.0)6.0 (5.0-6.1) 2nd to 3rd dose29.6 (26.9-36.4)19.9 (10.0-26.1)Diagnosis, n (%) Spondyloarthritis-713 (36.6) Rheumatoid arthritis-489 (25.1) Autoimmune disease, systemic+-420 (21.5) Inflammatory bowel disease-219 (11.2) Psoriasis-107 (5.5)Mean* antibody levels after 1st dose Week-84.16 (3.89 to 4.45)2.97 (2.83 to 3.12) Week-168.39 (7.81 to 9.02)5.04 (4.81 to 5.28) Week-325.02 (4.73 to 5.33)2.52 (2.32 to 2.74) Week-402.14 (1.95 to 2.35)1.01 (0.86 to 1.19)+ Systemic lupus, systemic sclerosis, Sjögren’s syndrome, vasculitis* Estimated marginal means adjusted for age and sex.Figure 1.ConclusionHumoral response to vaccination against SARS-CoV-2 was weaker in IMID patients compared to controls at all time points after the first vaccine dose and practically disappeared after 1 year. IMID patients can still achieve a good antibody response with a third dose even after a weak response with two doses.References[1]Simon D et al Nat Commun 2020Disclosure of InterestsNone declared
Collapse
|
2
|
POS1263 PRE-EXPOSURE PROPHYLAXIS FOR SARS-CoV-2 INFECTION WITH SUBCUTANEOUS CASIRIVIMAB/IMDEVIMAB IN PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundPatients with immune-mediated inflammatory diseases (IMID), particularly if treated with B-cell depleting therapies, show reduced humoral responses to SARS-CoV-2 vaccines and increased risk of severe COVID-19 (1,2). Since pre-exposure prophylaxis (PrEP) with monoclonal antibodies against SARS-CoV-2 proved effective in preventing infection and COVID-19 (3) in the general population, PrEP could be used for passive immunization of vaccine-refractory patients with IMIDs.ObjectivesTo evaluate the persistence of serum and salivary anti-SARS-CoV-2 IgG antibodies in vaccine-refractory patients with IMID after PrEP with casirivimab/imdevimab. Secondary outcomes were safety, SARS-CoV-2 infection, and adverse COVID-19 outcomes.MethodsWe performed a longitudinal analysis on anti-SARS-CoV-2 IgG titers in IMID patients who received a PrEP with 1200 mg of subcutaneous casirivimab/imdevimab due to high infection risk, as they had not developed an adequate humoral response at least 21 days after three COVID-19 vaccinations (Table 1). Serum and salivary anti-SARS-CoV-2 Spike IgG were quantified by ELISA (EUROIMMUN, Lübeck, Germany) before PrEP and after 1, 14, and 30 days. IgG levels are given as antibody ratios by dividing the optical density of the sample by that of the calibrator. A cutoff of ≥1.1 was considered positive. Safety as well as polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection and adverse COVID-19 outcomes (hospitalization, mechanical ventilation, death) after PrEP were recorded.Table 1.Baseline characteristics.N26Age, mean (SD)54 (14)Sex, n (%)Female15 (57.7)Male39 (42.3)Diagnosis, n (%)ANCA-associated vasculitis10 (38.5)Rheumatoid arthritis6 (23.1)Immunoglobulin deficiency4 (15.4)Systemic sclerosis2 (7.7)Psoriatic arthritis1 (3.8)Systemic Lupus Erythematosus1 (3.8)Non-infectious Uveitis1 (3.8)Multiple sclerosis1 (3.8)IgG4-related disease1 (3.8)Autoinflammatory syndrome1 (3.8)CD20-depletionRituximab, n (%)22 (84.6)Other therapies, n (%)Methotrexate6 (23.1)Immunoglobulins4 (15.4)Mycophenolate1 (3.8)Infliximab1 (3.8)CD19+ lymphocytes/mm3, median (IQR)0 (0-9)Serum total IgG, median (IQR)894 (745-987)SD, standard deviation; IQR, interquartile range; ANCA, anti-neutrophil cytoplasmic antibodies.ResultsWe obtained 92 serum and 75 saliva samples from 26 participants at four consecutive timepoints (Figure 1). Anti-SARS-CoV-2 IgG titers were observed in serum and saliva samples of all participants from day 1 and throughout 30 days after PrEP independently of diagnosis, therapy, total IgG, and peripheral CD19+ B-cells. Serum IgG increased rapidly at day 1 and plateaued from day 14 to 30 (Figure 1A), reaching similar levels as seen in healthy subjects after full vaccination (1), while saliva IgG increased steadily from administration up to day 14 and plateaued at day 30 (Figure 1B). No side effects were reported. Five patients (19.2%) had a close contact with a SARS-CoV-2-infected person, after which all but one remained asymptomatic and with a negative PCR test. The patient who tested positive developed mild COVID-19 with fever and cough.Figure 1.Temporal pattern and distribution of serum (A) and salivary (B) anti-SARS-CoV-2 IgG levels.Results from individual participants are represented as line (top) and scatter plots (bottom). Horizontal lines represent median values, the dotted horizontal line represents the positivity cutoff of 1.1.** p =0.0082; *** p <0.001; **** p <0.0001. mAbs: monoclonal antibodies.ConclusionSARS-CoV-2 PrEP induces stable serum and salivary antibody levels in IMID patients who did not respond to COVID-19 vaccination, regardless of pre-existing clinical and serological features. In IMID, PrEP with casirivimab/imdevimab is safe and has the potential to prevent infection and severe COVID-19.References[1]Simon D, et al. Ann rheum dis. 2021;80:1312-1316.[2]Fagni F et al, et al. Lancet Rheumatol. 2021; e724-e736.[3]Flonza I, et al. MedRxiv. 2021. doi: 10.1101/2021.11.10.21265889Disclosure of InterestsNone declared
Collapse
|
3
|
POS0699 SIMILAR EFFICACY AND DRUG SURVIVAL RATES OF BARICITINIB MONOTHERAPY AND BARICITINIB/METHOTREXATE COMBINATION THERAPY IN REAL-LIFE TREATMENT OF RHEUMATOID ARTHRITIS - RESULTS FROM A PROSPECTIVE COHORT OF BARICITINIB-TREATED PATIENTS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundIn clinical trials, baricitinib (BARI), in combination with methotrexate (MTX), demonstrated efficacy in patients with rheumatoid arthritis (RA) who have not responded adequately to conventional (cs)or biologic (b) DMARDs [1]. Since MTX is often not tolerated very well [2], BARI monotherapy may be preferable over BARI/MTX combination in some patients with RA. Therefore, real-life data on BARI mono- vs. combination therapy are needed to support such decisions.ObjectivesThe aim of our study was to evaluate the efficacy of BARI as mono- or combination therapy in a prospective, open label cohort of RA patients failing previous cs/bDMARD therapy.MethodsPatients with active RA (DAS28-ESR >3.2), fulfilling the ACR/EULAR 2010 classification criteria and failing previous cs/bDMARD therapy were included. All patients received BARI either as monotherapy or in combination with MTX based on the judgement of the treating physician. Demographics, medical history, disease activity parameters such as 66/68 TJC/SJC, composite scores such as DAS28-ESR, HAQ-DI, as well as medication were prospectively recorded every 3 months according to a pre-defined protocol. Informed consent and ethics approval (19_18 B) were obtained. To evaluate clinical efficacy, DA28 ESR responses was recorded at respective visit dates (until week 96). We estimated least-square mean DAS-28 scores over time using linear mixed effects models including time-group interactions. Kaplan-Meier method was used to estimate baricitinib survival and probability of remission over time.Results139 patients (98 women/41 men; aged 58.4 (12.8) years; mean disease duration of 9.7 years) were included between 4/2017-10/2021. Of these, 46 patients received a combination of BARI with MTX (BARI/MTX) and 93 patients BARI monotherapy. Baseline demographic and disease-specific characteristic were comparable between BARI/MTX and BARI patients (Table 1). Median follow up was 53.1 weeks (IQR 23.0-109.3). Decrease in DAS28-ESR showed a similar dynamics in BARI/MTX (baseline DAS28-ESR: 4.2+/-1.3; 48 weeks: 2.9 (95%CI 2.6 to 3.2)) and BARI (4.3+/-1.3; 48 weeks: 3.0 (95%CI 2.8 to 3.3)) with numerical but no significant differences (Figure 1a). 62% (95%CI 40 to 76%) patients in the BARI/MTX group and 51% (95%CI: 37 to 61%) patients in the BARI attained DAS28ESR remission after 48 weeks. Drug survival was comparable among BARI/MTX and BARI patients. (69 vs.67% at 1 year and 62 vs 56% at 2 years) (Figure 1b).ConclusionThese data show that BARI monotherapy is efficacious in real life treatment in RA patients with insufficient response to MTX. Clinical efficacy and drug survival is comparable between BARI monotherapy and BARI/MTX combo in a real-life setting.References[1]Genovese, M.C., et al., Baricitinib in Patients with Refractory Rheumatoid Arthritis. N Engl J Med, 2016.[2]Michaud, K., et al., Real-World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis. ACR Open Rheumatol, 2019AcknowledgementsThe analysis of the data of this study is partially financially supported by Elli Lilly.Disclosure of InterestsNone declared
Collapse
|
4
|
AB0385 BARICITINIB LEADS TO RAPID AND PERSISTENT RESOLUTION OF SYNOVITIS AS MEASURED BY HAND MRI IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA) FAILING cs/bDMARD THERAPY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundRA is characterized by synovial inflammation resulting in local bone loss [1]. Inhibitors of JAK/Stat pathways, such as baricitinib, demonstrated efficacy in reducing signs and symptoms of RA in clinical trials, however, little is known about their effects on synovitis and bone structure [2]. Preclinical and clinical observations suggest a positive effect JAK inhibitors on bone mass and microstructure, however no prospective, interventional clinical trial has been performed so far [3].ObjectivesThe aim of this study is to evaluate the effect of baricitinib on local inflammation (synovitis and osteitis) and bone structure (erosions) in RA patients failing on cs/bDMARD therapy using hand MRI.MethodsBAREBONE is a prospective, interventional, open label, monocentric single center study (EUDRACT 2018-001164-32 / NCT03701789) to assess the effect of baricitinib (4mg/day) on local MRI inflammation and structure in patients with active RA. Besides demographic and clinical characteristics, hand joint inflammation was assessed by magnetic resonance imaging (MRI) using a 1.5 Tesla scanner (Siemens Magnetom Aera T1w TSE cor, T2w TIRM cor, T2w TSE fat-sat trans, T1w TSE fat-sat trans + cor after KM;). at baseline, week 24 and week 48. Scans were assessed for synovitis, osteitis and bone erosions using the RAMRIS scoring system using two independent blinded readers (SK and SB). Intraclass correlation coefficients were calculated for total RAMRIS and synovitis, erosion and osteitis subscores and in a second step differences between cs and bDMARD failure were elaborated. Variables are summarized descriptively using means and 95% bootstrap confidence intervals for continuous outcomes and as number and percentages for categorical outcomes.ResultsThirty- two RA patients were screened and 30 patients were included (age: 53.4 [SD 12.6] years; sex: f/m N 24/6; disease duration: 3 [IQR 2.0 – 8.0] years; biologic naïve/bDMARD failure 16/14). 27 patients completed the trial while MRI data was available for 24 patients at week 48. Demographics and clinical characteristics can be seen in Table 1. Total RAMRIS scores slightly decreased from 20.6 (95% CI 14.4 -27.8) at baseline (BL) to 18.3 (11.5 -26.5) at week 48. The synovitis subscore mainly contributed to total RAMRIS reduction by significantly improving from 5.3 (4.0 - 6.8) at BL to 2.7 (1.5 - 4.0) at week 48 with a score change of -2.9 (-4.0 to -1.8). At week 48, 12 patients (44.4%) had no signs of synovitis compared to only 3 patients at BL. In contrast, RAMRIS osteitis subscores only marginally decreased from 4.9 (2.2 - 8.4) at BL to 4.0 (1.9 - 6.7) at week 48. RAMRIS erosion score remained stable over the 48-week observation time. A significant difference in RAMRIS synovitis change for biologic naïve -3.8 (-5.2 to -2.6) vs biologic failure -1.0 (-2.2 to 0.4 could be observed at week 48).With respect to clinical disease activity, DAS 28 score decreased from 4.8 (4.5 – 5.1) at BL to 2.9 (2.5 – 3.3) at week 48. Detailed results can be found in Table 1 and Figure 1. Intraclass coefficient (95%CI) for RAMRIS scoring was high for both readers 0.997 (0.994 to 0.998).Table 1.Demographics, DAS 28 ESR, RAMRIS total score and RAMRIS subset scores at baseline, week 24 and week 48 are shown as well as number of patients with improvement and resolution of synovitis.BaselineWeek 24Week 48N303027AgeMean [SD]53.5 (12.6)Genderfemalen [%]24 (80.0)malen [%]6 (20.0)Disease duration, yearsMedian (IQR)3.0 (2.0-8.0)DAS-28 ESRMean [95%CI]4.8 (4.5 to 5.1)3.0 (2.7 to 3.3)2.7 (2.4 to 3.0)MRI availablen [%]30 (100.0)28 (93.3)24 (88.9)RAMRIS totalMean [95%CI]20.6 (14.4 to 27.6)18.4 (12.6 to 25.4)18.3 (11.5 to 26.5)RAMRIS total changeMean [95%CI]0.0 (0.0 to 0.0)-2.1 (-4.0 to -0.4)-3.9 (-7.2 to -0.5)RAMRIS synovitisMean [95%CI]5.3 (3.9 to 6.9)3.5 (2.2 to 4.9)2.7 (1.5 to 4.0)RAMRIS synovitis changeMean [95%CI]0.0 (0.0 to 0.0)-1.8 (-2.5 to -1.0)-2.9 (-4.0 to -1.8)RAMRIS synovitis improvedpatients n [%]10 (33.3)13 (48.1)RAMRIS synovitis resolvedpatients n [%]10 (33.3)12 (44.4)RAMRIS osteitisMean [95%CI]4.9 (2.2 to 8.4)3.7 (1.5 to 6.2)4.0 (1.9 to 6.7)RAMRIS osteitis changeMean [95%CI]0.0 (0.0 to 0.0)-0.9 (-3.1 to 1.0)-1.9 (-5.7 to 1.1)RAMRIS osteitis improvedpatients n [%]2 (6.7)4 (14.8)RAMRIS erosionMean [95%CI]10.4 (7.3 to 14.6)11.2 (7.7 to 15.0)11.6 (7.5 to 16.6)RAMRIS erosion changeMean [95%CI]0.0 (0.0 to 0.0)0.6 (0.1 to 1.2)0.9 (0.0 to 2.1)RAMRIS erosion worsenedpatients n [%]2 (6.7)3 (11.1)ConclusionOur study shows that baricitinib primarily reduces MRI synovitis in RA patients that have previously failed csDMARD and bDMARD therapy and particularly in patients who are biologic naïve.References[1]McInnes, I.B. and G. Schett, The pathogenesis of rheumatoid arthritis. N Engl J Med, 2011.[2]Genovese, M.C., et al., Baricitinib in Patients with Refractory Rheumatoid Arthritis. N Engl J Med, 2016[3]Adam, S., et al., JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function. Sci Transl Med, 2020.AcknowledgementsLilly Deutschland GmbH funded the Barebone trialDisclosure of InterestsStephan Kemenes: None declared, Sara Bayat: None declared, David Simon Speakers bureau: Lilly Pharma Deutschland GmbH, Janssen, Consultant of: BMS, Pfizer, Sanofi, Abbvie, Janssen, Medac, Novartis,Lilly Deutschland GmbH, GileaBMS, Pfizer, Sanofi, Abbvie, Janssen, Medac, Novartis,Lilly Deutschland GmbH, Gilead, Amgend,, Grant/research support from: Novartis, Gilead, Abbvie, Lilly, Gerhard Krönke Speakers bureau: GSK, Novartis, Consultant of: GSK, Lilly, Novartis, Janssen, Grant/research support from: Lilly, Novartis, BMS, Janssen, Daniela Bohr: None declared, Larissa Valor: None declared, Fabian Hartmann: None declared, Louis Schuster: None declared, Koray Tascilar Speakers bureau: Gilead speaker, Consultant of: UCB, Lilly, Georg Schett Speakers bureau: Janssen, Abbvie, BMS, Lilly, Novartis, Roche, AMGEN, Gilead, UCB, Consultant of: Lilly, Novartis, Abbvie, Grant/research support from: Chugai, Lilly, Novartis, Arnd Kleyer Speakers bureau: Lilly, Novartis, Abbvie, Consultant of: BMS, Pfizer, Sanofi, Abbvie, Janssen, Medac, Novartis,Lilly Deutschland GmbH, Gilead, Amgen, Grant/research support from: Novartis, Lilly Deutschland GmbH, Gilead
Collapse
|
5
|
POS1384 NON-INVASIVE IN VIVO METABOLIC PROFILING OF INFLAMMATION IN JOINTS AND ENTHESES BY OPTOACOUSTIC IMAGING. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundAn in-depth metabolic characterization of joints and entheses at the tissue level can help in the early diagnosis and treatment selection for patients with inflammatory arthritis [1]. However, current knowledge about the metabolic profiles of synovitis and enthesitis is limited. Multispectral optoacoustic tomography (MSOT), a novel metabolic imaging technology, could be used to undertake metabolic profiling of joints and entheses non-invasively using near-infrared multispectral laser to stimulate tissues and detect the emitted acoustic energy, enabling quantification of tissue components in vivo based on differential absorbance at multiple wavelengths [2, 3].ObjectivesTo explore the metabolic characteristics of arthritis and enthesitis using MSOT.MethodsWe performed a cross sectional study on healthy controls (HC) and patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) (Table 1). Participants underwent clinical, ultrasound (US), and MSOT examination of metacarpophalangeal joints, wrists, entheses of lateral epicondyles, patellar, quadriceps and Achilles tendons. MSOT-derived hemoglobin, oxygen saturation, collagen and lipid levels were measured. We calculated scaled mean differences (SMD) between affected and unaffected joints and entheses as defined by clinical examination or US using linear mixed effects models.Table 1.Baseline characteristics.OverallHealthyPsARAN87363417Age, mean (SD)47.0 (15.7)34.7 (12.0)52.4 (11.5)62.5 (9.1)Sex, n (%) Female48 (55.2)18 (50.0)17 (50.0)13 (76.5) Male39 (44.8)18 (50.0)17 (50.0)4 (23.5)Tender joints, median (IQR)0 (0-2)0 (0-0)1 (0-5)2 (1-6)Swollen joints, median (IQR)0 (0-1)0 (0-0)0 (0-2)2 (1-6)Tender entheses, median (IQR)0 (0-2)0 (0-0)1 (0-3)0 (0-0)csDMARD, n (%)22 (25.3)-13 (38.3)9 (53.0)b-tsDMARD, n (%)31 (35.6)-20 (58.8)11 (64.7)SD, standard deviation; IQR, interquartile range; csDMARD, conventional synthetic disease modifying anti-rheumatic drug; b-tsDMARD, biologic or targeted synthetic disease modifying anti-rheumatic drug.ResultsWe obtained 1535 MSOT and 982 US scans from 87 participants (36 HC, 34 PsA, 17 RA). Entheseal tenderness was not associated with metabolic changes, whereas US enthesitis was associated with increased total hemoglobin, oxygen saturation and collagen content. In contrast, clinical and US arthritis showed increased hemoglobin levels but reduced oxygen saturation and reduced collagen content. Synovial hypertrophy was associated with increased lipid content in the joints (Figure 1).Figure 1.Scaled differences and 95% confidence intervals of MSOT-measured metabolite values by clinical and ultrasonographic findings of enthesitis (A-C) and arthritis (D-F). Two differences are plotted for each metabolite indicating two multispectral processing algorithms used for estimation. P values were adjusted for multiple testing using a false discovery rate of 5%. NS, not significant. sO2, oxygen saturation.ConclusionMSOT allows a non-invasive characterization of metabolic changes in arthritis and enthesitis. These findings can be interpreted as a reflection of increased synovial cellularity, collagen degradation, and metabolic demand in synovitis, and of an increased tissue apposition and vascularization in enthesitis. Our results suggest that synovitis and enthesitis do not only differ at the clinical and anatomical-functional level, but also exhibit divergent metabolic changes.References[1]Falconer J, et. al. Arthritis Rheumatol. 2018;70(7):984-99.[2]Regensburger AP, et. al. Biomedicines. 2021;9(5).[3]Regensburger AP, et al. Nature Medicine. 2019;25(12):1905-15.Conflict of InterestAR., FK, MW are co-inventors, together with iThera Medical GmbH, Germany on an EU patent application (no. EP 19 163 304.9) relating to a device and a method for analysis of optoacoustic data, an optoacoustic system and a computer program. All other authors declare no conflict of interest.AcknowledgementsWe thank Ms. Nairouz Al Ahmad, assistant medical technician (Department of Internal Medicine 3), for her assistance in conducting the study and Dr. Yi Qiu, PhD (iThera Medical GmbH) for her assistance in data analysis and interpretation.Disclosure of InterestsNone declared
Collapse
|
6
|
AB1346-HPR REAL-WORLD EFFECTIVENESS AND PERCEIVED USEFULNESS OF SYMPTOM CHECKERS IN RHEUMATOLOGY: INTERIM REPORT FROM THE PROSPECTIVE MULTICENTER BETTER STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1604] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Symptom checkers (SC) promise to reduce diagnostic delay, misdiagnosis and effectively guide patients through healthcare systems. They are increasingly used, however little evidence exists about their real-life effectiveness.Objectives:The aim of this study was to evaluate the diagnostic accuracy, usage time, usability and perceived usefulness of two promising SC, ADA (www.ada.com) and Rheport (www.rheport.de). Furthermore, symptom duration and previous symptom checking was recorded.Methods:Cross-sectional interim clinical data from the first of three recruiting centers from the prospective, real-world, multicenter bETTeR-study (DKRS DRKS00017642) was used. Patients newly presenting to a secondary rheumatology outpatient clinic between September and December 2019 completed the ADA and Rheport SC. The time and answers were recorded and compared to the patient’s actual diagnosis. ADA provides up to 5 disease suggestions, Rheport calculates a risk score for rheumatic musculoskeletal diseases (RMDs) (≥1=RMD). For both SC the sensitivity, specificity was calculated regarding RMDs. Furthermore, patients completed a survey evaluating the SC usability using the system usability scale (SUS), perceived usefulness, previous symptom checking and symptom duration.Results:Of the 129 consecutive patients approached, 97 agreed to participate. 38% (37/97) of the presenting patients presented with an RMD (Figure 1). Mean symptom duration was 146 weeks and a mean number of 10 physician contacts occurred previously, to evaluate current symptoms. 56% (54/96) had previously checked their symptoms on the internet using search engines, spending a mean of 6 hours. Rheport showed a sensitivity of 49% (18/37) and specificity of 58% (35/60) concerning RMDs. ADA’s top 1 and top 5 disease suggestions concerning RMD showed a sensitivity of 43% (16/37) and 54% (20/37) and a specificity of 58% (35/60) and 52% (31/60), respectively. ADA listed the correct diagnosis of the patients with RMDs first or within the first 5 disease suggestions in 19% (7/37) and 30% (11/37), respectively. The average perceived usefulness for checking symptoms using ADA, internet search engines and Rheport was 3.0, 3.5 and 3.1 on a visual analog scale from 1-5 (5=very useful). 61% (59/96) and 64% (61/96) would recommend using ADA and Rheport, respectively. The mean SUS score of ADA and Rheport was 72/100 and 73/100. The mean usage time for ADA and Rheport was 8 and 9 minutes, respectively.Conclusion:This is the first prospective, real-world, multicenter study evaluating the diagnostic accuracy and other features of two currently used SC in rheumatology. These interim results suggest that diagnostic accuracy is limited, however SC are well accepted among patients and in some cases, correct diagnosis can be provided out of the pocket within few minutes, saving valuable time.Figure:Acknowledgments:This study was supported by an unrestricted research grant from Novartis.Disclosure of Interests:Johannes Knitza Grant/research support from: Research Grant: Novartis, Jacob Mohn: None declared, Christina Bergmann: None declared, Eleni Kampylafka Speakers bureau: Novartis, BMS, Janssen, Melanie Hagen: None declared, Daniela Bohr: None declared, Elizabeth Araujo Speakers bureau: Novartis, Lilly, Abbott, Matthias Englbrecht Grant/research support from: Roche Pharma, Chugai Pharma Europe, Consultant of: AbbVie, Roche Pharma, RheumaDatenRhePort GbR, Speakers bureau: AbbVie, Celgene, Chugai Pharma Europe, Lilly, Mundipharma, Novartis, Pfizer, Roche Pharma, UCB, David Simon Grant/research support from: Else Kröner-Memorial Scholarship, Novartis, Consultant of: Novartis, Lilly, Arnd Kleyer Consultant of: Lilly, Gilead, Novartis,Abbvie, Speakers bureau: Novartis, Lilly, Timo Meinderink: None declared, Wolfgang Vorbrüggen: None declared, Cay-Benedict von der Decken: None declared, Stefan Kleinert Shareholder of: Morphosys, Grant/research support from: Novartis, Consultant of: Novartis, Speakers bureau: Abbvie, Novartis, Celgene, Roche, Chugai, Janssen, Andreas Ramming Grant/research support from: Pfizer, Novartis, Consultant of: Boehringer Ingelheim, Novartis, Gilead, Pfizer, Speakers bureau: Boehringer Ingelheim, Roche, Janssen, Jörg Distler Grant/research support from: Boehringer Ingelheim, Consultant of: Boehringer Ingelheim, Paid instructor for: Boehringer Ingelheim, Speakers bureau: Boehringer Ingelheim, Peter Bartz-Bazzanella: None declared, Georg Schett Speakers bureau: AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, Roche and UCB, Axel Hueber Grant/research support from: Novartis, Lilly, Pfizer, Consultant of: Abbvie, BMS, Celgene, Gilead, GSK, Lilly, Novartis, Speakers bureau: GSK, Lilly, Novartis, Martin Welcker Grant/research support from: Abbvie, Novartis, UCB, Hexal, BMS, Lilly, Roche, Celgene, Sanofi, Consultant of: Abbvie, Actelion, Aescu, Amgen, Celgene, Hexal, Janssen, Medac, Novartis, Pfizer, Sanofi, UCB, Speakers bureau: Abbvie, Aescu, Amgen, Biogen, Berlin Chemie, Celgene, GSK, Hexal, Mylan, Novartis, Pfizer, UCB
Collapse
|
7
|
Investing in tomorrow: healthcare tithing. THE HEALTHCARE FORUM JOURNAL 1998; 41:36-8. [PMID: 10185470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
|
8
|
Inducible L-arginine/nitric oxide pathway in human internal mammary artery and saphenous vein. THE AMERICAN JOURNAL OF PHYSIOLOGY 1995; 268:H1122-32. [PMID: 7900866 DOI: 10.1152/ajpheart.1995.268.3.h1122] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
To characterize the L-arginine/nitric oxide (NO) pathway in human vascular smooth muscle (VSM), contractile responses of isolated internal mammary arteries (IMA) and saphenous veins (SV) were observed after induction of NO synthase by interleukin-1 beta (IL-1 beta) or by lipopolysaccharide (LPS). In IL-1 beta-treated endothelium-denuded rings, contractile responses to phenylephrine were reduced in SV rings only. Maximum phenylephrine-induced contraction was depressed by approximately 50%. This was not modified by the presence of indomethacin, NG-nitro-L-arginine methyl ester (L-NAME), or methylene blue (MeB). In LPS-treated vessels, contractile responses were depressed in both SV and IMA rings (40%), and this was not affected by indomethacin. In SV, L-NAME, NG-monomethyl-L-arginine, or MeB did not affect the inhibitory effect of LPS, whereas the effect was reversed in IMA by these inhibitors. In LPS-treated IMA, but not in SV, exogenous L-arginine evoked significant vasodilation (20%). We conclude that VSM of the human IMA possesses an L-arginine/NO pathway inducible by LPS. In SV, LPS or IL-1 beta treatment inhibits contraction by an unidentified system that is not dependent on NO synthase or on guanylate cyclase activities.
Collapse
|
9
|
Abstract
In these studies blood pressure responses to intracerebroventricular (i.c.v.) infusions were recorded in anesthetized rats. NO donors caused a fall in blood pressure, whereas L-NAME, which blocks the enzyme (NOS) that produces NO, caused a rise in blood pressure. Calcium, i.c.v., stimulates NOS to lower blood pressure. The depressor action of NO is reduced by blocking the action of cGMP. This central NO/cGMP system is tonically active to maintain blood pressure at a normal level.
Collapse
|
10
|
Light-activated release of nitric oxide from vascular smooth muscle of normotensive and hypertensive rats. Biochem Biophys Res Commun 1994; 200:213-8. [PMID: 8166690 DOI: 10.1006/bbrc.1994.1436] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
A porphyrinic sensor was used to monitor nitric oxide release from vascular smooth muscle in response to exposure to ultraviolet light. Aortic rings exposed to UV light relaxed with a time course that parallels this observed NO release. With repeated UV light treatments, the magnitude of the relaxations diminished, suggesting that a store of NO was being exhausted. Photorelaxation in response to UV light was studied in aortic ring from two types of hypertensive rats, genetic (SHRSP) and nitroarginine-induced. These aortic rings showed greater photorelaxation and evidenced less tolerance than did aortic rings from control normotensive rats. Since NO synthase activity is depressed in both types of hypertension, it appears, paradoxically, that the UV light-releasable store of NO is augmented when NO synthase activity is depressed.
Collapse
|
11
|
Abstract
A porphyrinic sensor was used to monitor nitric oxide released from cultured endothelial and vascular smooth muscle cells obtained from genetically hypertensive rats and from a normotensive reference strain of rats. Endothelial cell nitric oxide synthase (the constitutive enzyme) was stimulated with bradykinin, and vascular smooth muscle cell nitric oxide synthase (the inducible enzyme) was induced with interleukin-1 beta. Both types of cells from hypertensive rats released less nitric oxide than did cells from normotensive rats. The observed deficient nitric oxide release from endothelial and smooth muscle cells may contribute to the elevated vascular tone and increased cell growth described in hypertension.
Collapse
|
12
|
QA orientation and reporting: problem areas for boards. TRUSTEE : THE JOURNAL FOR HOSPITAL GOVERNING BOARDS 1989; 42:15, 27. [PMID: 10294820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
13
|
Endothelium-mediated spontaneous response in aortic rings of deoxycorticosterone acetate-hypertensive rats. Hypertension 1989; 13:256-61. [PMID: 2921080 DOI: 10.1161/01.hyp.13.3.256] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Aortic rings isolated from normotensive Sprague-Dawley rats (CONT) exhibited spontaneous tone when the preparations were stretched. After administering deoxycorticosterone acetate (DOCA), the rats became hypertensive, and this spontaneous tone increased remarkably. The spontaneous tone was dependent on the extracellular calcium concentration. Incubation with the calcium entry blocker D-600 attenuated the spontaneous response to a greater degree in rings from DOCA rats than in rings from CONT rats. Nifedipine relaxed the already developed spontaneous tone. Removal of the endothelium greatly depressed spontaneous tone, but did not diminish the contraction caused by norepinephrine. On the basis of our findings, we conclude that 1) spontaneous tone depends on calcium influx, presumably through specific stretch-operated membrane channels, 2) these stretch-dependent channels are blocked by D-600 and nifedipine, 3) spontaneous tone is enhanced in DOCA hypertension, and 4) the endothelium appears to act as a receptor for stretch, mediating--at least in part--the spontaneous contractile response by releasing a constrictor agent.
Collapse
|
14
|
Abstract
The plasma membrane is composed of proteins embedded in a discontinuous fashion in a lipid bilayer. These proteins maintain the integrity of the membrane and play fundamental roles as ion transport channels and as receptors for agents that regulate cell function. The membrane is therefore an important regulator of vascular smooth muscle contraction. The plasma membrane in the hypertensive animal exhibits abnormal permeability for monovalent ions and defective calcium handling. This is reflected in fewer calcium-binding sites and, as a result, in deficient membrane stabilization. These defects have been identified in several cell types, including lymphocytes, red blood cells, adipocytes, and vascular smooth muscle cells. Evidence presented in the current review suggests that hypertension is associated with a generalized membrane defect. Abnormalities in ion transport in vascular smooth muscle cells are the most relevant to the pathogenesis of hypertension since they could be directly responsible for the rise in blood pressure. We hypothesize that the impaired stabilizing effect of calcium in vascular smooth muscle cells of hypertensive subjects renders the membrane more excitable and that this in turn leads to increased vascular reactivity and higher peripheral resistance. Peripheral vascular reactivity usually is increased in hypertension, suggesting increased responsiveness of the smooth muscle cells. Possible abnormalities of the several components of the contractile process of these cells have been investigated for the role they might play in this altered response. Abnormalities in the plasma membrane have been most clearly defined and are emphasized in this review.
Collapse
|
15
|
|